Exane Derivatives’s Regenxbio RGNX Stock Holding History

Exane Derivatives’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,180	Closed	-$175K	–	947
2021 Q3	$175K	Sell	4,180 -326	-7%	-$11.7K	0.04%	427
2021 Q2	$165K	Buy	4,506 +348	+8%	+$12.4K	0.04%	449
2021 Q1	$142K	Buy	4,158 +200	+5%	+$8.53K	0.04%	345
2020 Q4	$180K	Buy	3,958 +813	+26%	+$28.4K	0.05%	324
2020 Q3	$86.5K	Buy	3,145 +431	+16%	+$14.1K	0.03%	322
2020 Q2	$100K	Buy	2,714 +2,700	+19,286%	+$101K	0.03%	296
2020 Q1	$453	Hold	14	–	–	﹤0.01%	612
2019 Q4	$666	Hold	14	–	–	﹤0.01%	584
2019 Q3	$498	Hold	14	–	–	﹤0.01%	585
2019 Q2	$719	Hold	14	–	–	﹤0.01%	575
2019 Q1	$802	Sell	14 -252	-95%	-$12.5K	﹤0.01%	513
2018 Q4	$11.2K	Hold	266	–	–	﹤0.01%	456
2018 Q3	$20.7K	Sell	266 -3,734	-93%	-$269K	﹤0.01%	416
2018 Q2	$284K	Hold	4,000	–	–	0.05%	225
2018 Q1	$114K	Buy	+4,000	New	+$116K	0.02%	284

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exane Derivatives's RGNX Position: Q4 2021 in Review

Exane Derivatives sold out of Regenxbio (RGNX) in Q4 2021, closing a stake of 4,180 shares — an estimated $175K sold.

Exane Derivatives first reported a position in RGNX in Q1 2018 and held it in 15 quarters. The position peaked at $284K in Q2 2018. 172 funds tracked by Wall St. Rank hold RGNX as of Q4 2021.

Exane Derivatives reported no remaining Regenxbio position as of Q4 2021 after selling out during the quarter.
Exane Derivatives sold 4,180 Regenxbio shares in Q4 2021, an estimated $175K.
Exane Derivatives first reported a position in Regenxbio in Q1 2018 and held it in 15 quarters.
Exane Derivatives's Regenxbio position peaked at $284K in Q2 2018.
172 funds tracked by Wall St. Rank held Regenxbio as of Q4 2021.

Based on Exane Derivatives's 13F filing for Q4 2021, filed 28 Jan 2022.